Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies. After patients with acute monocytic leukemia (AML) ...

In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

With this approval, LabPMM is helping to transform the landscape of AML research, treatment and drug development. By using MRD as a surrogate endpoint in clinical trials, instead of relying solely on ...

Invivoscribe's subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), has secured New York State (NYS) approval for the NPM1 MRD Assay, marking an advancement to combat acute myeloid ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

Molecular minimal residual disease (MRD) testing during the first 4 days of induction therapy does not differentiate responders and nonresponders and should not be used in predicting clinical response ...

Study findings shed a light on the role of minimal residual disease (MRD) status and type of postremission therapy in the prognosis of patients with intermediate-risk acute myeloid leukemia (AML) who ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON) today announced, following receipt of minutes from its End-of-Phase 2 meeting with the U.S.

Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay.

(MENAFN- AETOSWire) (BUSINESS WIRE )--Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM) has received approval from New ...